{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:47:07Z","timestamp":1788353227651,"version":"build-2803163510"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bioorg.2023.106869","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:05:47Z","timestamp":1695211547000},"page":"106869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Historical perspectives and recent advances in small molecule ligands of selective\/biased\/multi-targeted \u03bc\/\u03b4\/\u03ba opioid receptor (2019\u20132022)"],"prefix":"10.1016","volume":"141","author":[{"given":"Ye","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106869_b0005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/383819a0","article-title":"Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the \u00b5-opioid-receptor gene","volume":"383","author":"Matthes","year":"1996","journal-title":"Nature"},{"issue":"Supplement","key":"10.1016\/j.bioorg.2023.106869_b0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","article-title":"Clinical pharmacology of opioids for pain","volume":"18","author":"Inturrisi","year":"2002","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.bioorg.2023.106869_b0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0038-1676477","article-title":"Pain management in enhanced recovery after surgery (eras) protocols","volume":"32","author":"Simpson","year":"2019","journal-title":"Clin. Colon Rectal Surg."},{"key":"10.1016\/j.bioorg.2023.106869_b0020","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1213\/ANE.0000000000002403","article-title":"The US opioid crisis: current federal and state legal issues","volume":"125","author":"Soelberg","year":"2017","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.bioorg.2023.106869_b0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.semperi.2019.01.001","article-title":"The united states opioid epidemic","volume":"43","author":"Lyden","year":"2019","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.bioorg.2023.106869_b0030","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.bja.2019.03.006","article-title":"Hot topics in opioid pharmacology: mixed and biased opioids","volume":"122","author":"Azzam","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.bioorg.2023.106869_b0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bph.12599","article-title":"Positive allosteric modulators of the \u03bc-opioid receptor: a novel approach for future pain medications","volume":"172","author":"Burford","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0040","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/bph.13823","article-title":"Allostery at opioid receptors: modulation with small molecule ligands","volume":"175","author":"Livingston","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.vh.2014.10.002","article-title":"Bioinformatics and evolution of vertebrate nociceptin and opioid receptors","volume":"97","author":"Stevens","year":"2015","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.bioorg.2023.106869_b0050","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors - improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0055","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12630-013-9989-4","article-title":"Butorphanol prevents morphine-induced pruritus without increasing pain and other side effects: a systematic review of randomized controlled trials","volume":"60","author":"Du","year":"2013","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.bioorg.2023.106869_b0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0026-895X(25)10234-4","article-title":"Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C","volume":"48","author":"Pei","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0065","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1074\/jbc.M305796200","article-title":"Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance","volume":"279","author":"McLaughlin","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0070","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/sj.emboj.7600334","article-title":"Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375","volume":"23","author":"Schulz","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2023.106869_b0075","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aas9609","article-title":"Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid \u03bc-opioid receptor desensitization","volume":"11","author":"Miess","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bioorg.2023.106869_b0080","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34989","article-title":"Cellular tolerance at the \u00b5-opioid receptor is phosphorylation dependent","volume":"7","author":"Arttamangkul","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2023.106869_b0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.tips.2011.05.002","article-title":"\u03b2-Arrestin-mediated receptor trafficking and signal transduction","volume":"32","author":"Shenoy","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1126\/science.283.5402.655","article-title":"Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes","volume":"283","author":"Luttrell","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2023.106869_b0095","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1124\/pr.111.004598","article-title":"Functional selectivity at the \u03bc-opioid receptor: implications for understanding opioid analgesia and tolerance","volume":"63","author":"Raehal","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2023.106869_b0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1515\/bmc-2018-0013","article-title":"Biased receptor functionality versus biased agonism in G-protein-coupled receptors","volume":"9","author":"Franco","year":"2018","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.bioorg.2023.106869_b0105","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2023.106869_b0110","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2023.106869_b0120","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/jpet.119.258640","article-title":"A Novel G Protein-Biased Agonist at the delta Opioid Receptor with Analgesic Efficacy in Models of Chronic Pain","volume":"372","author":"Conibear","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2023.106869_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/ph12020095","article-title":"Therapeutic Potential of Kappa Opioid Agonists","volume":"12","author":"Beck","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2023.106869_b0135","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1523\/JNEUROSCI.5679-07.2008","article-title":"p38: the link between the kappa-opioid receptor and dysphoria","volume":"28","author":"Carr","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2023.106869_b0140","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","article-title":"Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons","volume":"35","author":"Ehrich","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2023.106869_b0145","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","article-title":"Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.bioorg.2023.106869_b0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2019.03.006","article-title":"Bifunctional opioid receptor ligands as novel analgesics","volume":"151","author":"Cunningham","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2023.106869_b0155","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors - improved analgesics with reduced side effects?","volume":"175","author":"Gunther","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2015.11.028","article-title":"Multitarget opioid ligands in pain relief: New players in an old game","volume":"108","author":"Turnaturi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0165","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3390\/12040896","article-title":"4\u2019-Acetamidochalcone Derivatives as Potential Antinociceptive Agents","volume":"12","author":"De Campos-Buzzi","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.106869_b0170","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/1521-4184(200110)334:10<332::AID-ARDP332>3.0.CO;2-O","article-title":"Antinociceptive properties of chalcones. Structure-activity relationships, Archiv Der","volume":"334","author":"Corr\u00eaa","year":"2001","journal-title":"Pharmazie"},{"key":"10.1016\/j.bioorg.2023.106869_b0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ardp.200600049","article-title":"Antinociceptive effects of synthetic chalcones obtained from xanthoxyline","volume":"339","author":"de Campos-Buzzi","year":"2006","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bioorg.2023.106869_b0180","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1515\/znc-2008-11-1208","article-title":"Antinociceptive Activity and Preliminary Structure-Activity Relationship of Chalcone-Like Compounds","volume":"63","author":"Corr\u00eaa","year":"2008","journal-title":"Zeitschrift F\u00fcr Naturforschung C"},{"key":"10.1016\/j.bioorg.2023.106869_b0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1078\/094471103321659924","article-title":"Analgesic and antiinflammatory effects of chalcones isolated from Myracrodruon urundeuva allemao","volume":"10","author":"Viana","year":"2003","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2023.106869_b0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2010.08.030","article-title":"Antinociceptive activity of a synthetic chalcone, flavokawin B on chemical and thermal models of nociception in mice","volume":"647","author":"Mohamad","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0195","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1089\/jmf.2015.0092","article-title":"Chemical Composition and Antinociceptive Potential of Campomanesia reitziana Fruits","volume":"19","author":"Nesello","year":"2016","journal-title":"J. Med. Food"},{"key":"10.1016\/j.bioorg.2023.106869_b0200","doi-asserted-by":"crossref","first-page":"e01376","DOI":"10.1016\/j.heliyon.2019.e01376","article-title":"Chalcone derivatives: synthesis, in vitro and in vivo evaluation of their anti-anxiety, anti-depression and analgesic effects","volume":"5","author":"Higgs","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2023.106869_b0205","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/13543776.2011.596529","article-title":"& Hadjipavlou-Litina, D., Recent progress in therapeutic applications of chalcones","volume":"21","author":"Katsori","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2023.106869_b0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmech.2006.09.019","article-title":"A review of anti-infective and anti-inflammatory chalcones","volume":"42","author":"Nowakowska","year":"2007","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0215","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00210-015-1167-5","article-title":"What is the main mechanism of tramadol?","volume":"388","author":"Minami","year":"2015","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.1977.tb41843.x","article-title":"ACTH: a short introductory review","volume":"297","author":"Schwyzer","year":"1977","journal-title":"Annals New York Academy of Scicnces"},{"key":"10.1016\/j.bioorg.2023.106869_b0225","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejphar.2015.05.013","article-title":"Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs","volume":"763","author":"Lee","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0230","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/jm00168a028","article-title":"Design of peptidomimetic.delta. opioid receptor antagonists using the message-address concept","volume":"33","author":"Portoghese","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0235","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0165-6147(89)90267-8","article-title":"Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists","volume":"10","author":"Portoghese","year":"1989","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0240","doi-asserted-by":"crossref","unstructured":"G.R. Dondio, S.; Eggleston, D. S.; Artico, M.; Petrillo, P.; Petrone, G.; Visentin, L.; Farina, C.; Vecchietti, V.; Clarke, G. D., Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept, Journal of Medicinal Chemistry, 40 (1997) 3192-3198.","DOI":"10.1021\/jm9608218"},{"key":"10.1016\/j.bioorg.2023.106869_b0245","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.bmcl.2008.12.093","article-title":"14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies","volume":"19","author":"Li","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106869_b0250","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1016\/j.bmc.2013.08.042","volume":"21","author":"Zaidi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0255","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.bmcl.2014.04.098","article-title":"Design and synthesis of quinolinopropellane derivatives with selective delta opioid receptor agonism","volume":"24","author":"Nagase","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106869_b0260","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bmcl.2016.11.057","article-title":"Benzylideneoxymorphone: A new lead for development of bifunctional mu\/delta opioid receptor ligands","volume":"27","author":"Healy","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106869_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112070","article-title":"Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carb oxamide as novel potent analgesic","volume":"189","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0270","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s002100000266","article-title":"Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor","volume":"362","author":"Gillen","year":"2000","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0275","first-page":"285","article-title":"Design","volume":"12","author":"Huang","year":"2021","journal-title":"Synthesis, and Structure-Activity Relationship Exploration of Alkyl\/Phenylalkyl Piperidine Analogues as Novel Highly Potent and Selective mu Opioid Receptor Agonists, ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2023.106869_b0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejmech.2018.06.017","article-title":"Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review","volume":"155","author":"Turnaturi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0285","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejmech.2018.02.046","article-title":"Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review","volume":"148","author":"Turnaturi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23030677","article-title":"Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists","volume":"23","author":"Turnaturi","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.106869_b0295","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.bmc.2010.06.005","article-title":"Evaluation of N-substitution in 6,7-benzomorphan compounds","volume":"18","author":"Pasquinucci","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0300","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.lfs.2012.04.041","article-title":"Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand","volume":"90","author":"Parenti","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0305","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lfs.2011.10.024","article-title":"The benzomorphan-based LP1 ligand is a suitable MOR\/DOR agonist for chronic pain treatment","volume":"90","author":"Pasquinucci","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0310","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuropharm.2013.03.008","article-title":"The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures","volume":"71","author":"Parenti","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2023.106869_b0315","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.bmc.2016.05.005","article-title":"Evaluation of N-substituent structural variations in opioid receptor profile of LP1","volume":"24","author":"Pasquinucci","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0320","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.bmc.2017.07.021","article-title":"Development of novel LP1-based analogues with enhanced delta opioid receptor profile","volume":"25","author":"Pasquinucci","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2019.01.031","article-title":"Simultaneous targeting of MOR\/DOR: A useful strategy for inflammatory pain modulation","volume":"847","author":"Pasquinucci","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0330","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1007\/s12035-019-1607-1","article-title":"Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain","volume":"56","author":"Vicario","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2023.106869_b0335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejmech.2019.02.043","article-title":"(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu\/delta opioid receptor agonist","volume":"168","author":"Pasquinucci","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0340","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1021\/acsmedchemlett.9b00549","article-title":"Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist\/DOR-Antagonist to Biased\/Unbiased MOR Agonists","volume":"11","author":"Pasquinucci","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106869_b0345","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2023.106869_b0350","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/0024-3205(91)90154-4","article-title":"Opioid receptor-coupled second messenger systems","volume":"48","author":"Childers","year":"1991","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0355","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.cellsig.2012.08.002","article-title":"Selective interactions of spinophilin with the C-terminal domains of the delta- and mu-opioid receptors and G proteins differentially modulate opioid receptor signaling","volume":"24","author":"Fourla","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2023.106869_b0360","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1124\/jpet.105.089946","article-title":"Expression of the third intracellular loop of the delta-opioid receptor inhibits signaling by opioid receptors and other G protein-coupled receptors","volume":"315","author":"Morou","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bioorg.2023.106869_b0365","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cellsig.2014.09.023","article-title":"RGS2 and RGS4 proteins: New modulators of the kappa-opioid receptor signaling","volume":"27","author":"Papakonstantinou","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2023.106869_b0370","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/138945012798868470","article-title":"The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction","volume":"13","author":"Georgoussi","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2023.106869_b0375","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/mol.107.039842","article-title":"Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation","volume":"73","author":"Zheng","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0380","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13543784.2017.1260544","article-title":"Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain","volume":"26","author":"Grosch","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bioorg.2023.106869_b0385","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fphar.2019.00124","article-title":"Therapeutic Potential of Targeting ss-Arrestin","volume":"10","author":"Bond","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23736-2","article-title":"Site selective C-H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy","volume":"12","author":"Bhowmik","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2023.106869_b0395","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1126\/science.1219218","article-title":"Structural basis for allosteric regulation of GPCRs by sodium ions","volume":"337","author":"Liu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2023.106869_b0400","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature12944","article-title":"Molecular control of \u03b4-opioid receptor signalling","volume":"506","author":"Fenalti","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2023.106869_b0405","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41586-022-05588-y","article-title":"Structure-based design of bitopic ligands for the \u00b5-opioid receptor","volume":"613","author":"Faouzi","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2023.106869_b0410","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1038\/s41598-020-70493-1","article-title":"Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists","volume":"10","author":"Kaserer","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2023.106869_b0415","doi-asserted-by":"crossref","first-page":"21548","DOI":"10.1038\/srep21548","article-title":"mu Opioid receptor: novel antagonists and structural modeling","volume":"6","author":"Kaserer","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2023.106869_b0420","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1021\/acschemneuro.1c00149","article-title":"Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom","volume":"12","author":"Chakraborty","year":"2021","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2023.106869_b0425","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1111\/bph.14805","article-title":"Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine","volume":"176","author":"Kudla","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0430","article-title":"Structure-Based Evolution of G Protein-Biased \u03bc-Opioid Receptor Agonists","volume":"61","author":"Wang","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2023.106869_b0435","doi-asserted-by":"crossref","unstructured":"X.T. Chen, P. Pitis, G. Liu, C. Yuan, D. Gotchev, C.L. Cowan, D.H. Rominger, M. Koblish, S.M. Dewire, A.L. Crombie, J.D. Violin, D.S. Yamashita, Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain, J Med Chem, 56 (2013) 8019-8031.","DOI":"10.1021\/jm4010829"},{"key":"10.1016\/j.bioorg.2023.106869_b0440","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into micro-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2023.106869_b0445","doi-asserted-by":"crossref","first-page":"9261","DOI":"10.1021\/acsomega.7b01452","article-title":"Discovery of SHR9352: A Highly Potent G Protein-Biased mu-Opioid Receptor Agonist","volume":"2","author":"Li","year":"2017","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2023.106869_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113986","article-title":"Synthesis, biological, and structural explorations of a series of mu-opioid receptor (MOR) agonists with high G protein signaling bias","volume":"228","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0455","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","article-title":"Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor","volume":"185","author":"Zhuang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2023.106869_b0460","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/acs.jmedchem.8b01158","article-title":"Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[(4'-pyridyl)carboxa mido]morphinan (NAP) Derivatives as mu\/kappa Opioid Receptor Dual Selective Ligands","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0465","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"A potent naturally occurring nonnitrogenous \u03ba opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0470","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.114.214239","article-title":"Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome","volume":"350","author":"Salaga","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2023.106869_b0475","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0269881119849821","article-title":"Salvindolin elicits opioid system-mediated antinociceptive and antidepressant-like activities","volume":"33","author":"Keasling","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0480","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1021\/jm048963m","article-title":"Neoclerodane Diterpenes as a Novel Scaffold for \u03bc Opioid Receptor Ligands","volume":"48","author":"Harding","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0485","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/np060094b","article-title":"Synthesis of Salvinorin A Analogues as Opioid Receptor Probes","volume":"69","author":"Tidgewell","year":"2006","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2023.106869_b0490","doi-asserted-by":"crossref","first-page":"e202100684","DOI":"10.1002\/cmdc.202100684","article-title":"6,5-Fused Ring, C2-Salvinorin Ester, Dual Kappa and Mu Opioid Receptor Agonists as Analgesics Devoid of Anxiogenic Effects","volume":"17","author":"Akins","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2023.106869_b0495","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.1222044110","article-title":"Identification of a \u03bc-\u03b4 opioid receptor heteromer-biased agonist with antinociceptive activity","volume":"110","author":"Gomes","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0500","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/j.pain.0000000000001768","article-title":"Activation of \u03bc-\u03b4 opioid receptor heteromers inhibits neuropathic pain behavior in rodents","volume":"161","author":"Tiwari","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.bioorg.2023.106869_b0505","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1021\/acs.jmedchem.0c00901","article-title":"Synthesis and Pharmacology of a Novel mu-delta Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template","volume":"63","author":"Faouzi","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0510","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4155\/fmc.13.215","article-title":"Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications","volume":"6","author":"Vardanyan","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0515","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56519","article-title":"Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site","volume":"10","author":"Uprety","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2023.106869_b0520","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","article-title":"Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor","volume":"172","author":"Che","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2023.106869_b0525","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/acschemneuro.5b00137","article-title":"Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction","volume":"6","author":"V\u00e1radi","year":"2015","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2023.106869_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105734","article-title":"NB-33, a bioreversible opioid derivative of Nalbuphine, shows enhanced pharmacodynamics","volume":"159","author":"Voronkov","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105093","article-title":"A dual system platform for drug metabolism: Nalbuphine as a model compound","volume":"141","author":"Liang","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0540","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11306-013-0605-y","article-title":"New finding of nalbuphine metabolites in men: NMR spectroscopy and UPLC\u2013MS\/MS spectrometry assays in a pilot human study","volume":"10","author":"Wang","year":"2013","journal-title":"Metabolomics"},{"key":"10.1016\/j.bioorg.2023.106869_b0545","doi-asserted-by":"crossref","first-page":"13152","DOI":"10.1021\/acs.jmedchem.1c00910","article-title":"Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective","volume":"64","author":"Xiong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0550","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jps.2600750226","article-title":"Buccal and Oral Bioavailability of Nalbuphine in Rats","volume":"75","author":"Hussain","year":"1986","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0555","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1213\/01.ANE.0000078589.90903.EF","article-title":"The antinociceptive effect of nalbuphine and its long-acting esters in rats","volume":"97","author":"Chu","year":"2003","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.bioorg.2023.106869_b0560","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbb.2017.04.006","article-title":"Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development","volume":"164","author":"Negus","year":"2018","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.bioorg.2023.106869_b0565","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/acs.biochem.0c00498","article-title":"FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR-DOR Heteromer","volume":"60","author":"Akgun","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2023.106869_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116552","article-title":"Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward delta and kappa opioid receptors","volume":"53","author":"Uenohara","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0575","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1016\/j.bmc.2015.08.036","article-title":"Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain","volume":"23","author":"Nakajima","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0580","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1016\/j.bmc.2010.04.069","article-title":"Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists","volume":"18","author":"Yamaotsu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0585","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/128_2010_84","article-title":"3D-pharmacophore identification for kappa-opioid agonists using ligand-based drug-design techniques","volume":"299","author":"Yamaotsu","year":"2011","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0590","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jphs.2015.11.008","article-title":"Nalfurafine hydrochloride, a selective \u03ba opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys","volume":"130","author":"Nakao","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0595","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1021\/acschemneuro.2c00526","article-title":"Characterization of a Potential KOR\/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues","volume":"13","author":"Li","year":"2022","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2023.106869_b0600","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/0024-3205(82)90132-1","article-title":"Properties of a selective kappa agonist, U-50,488H","volume":"31","author":"Lahti","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2023.106869_b0605","doi-asserted-by":"crossref","unstructured":"A.T. Takashi Endoh., Naoki lzumimoto., Tomohiko Suzuki., Akiyoshi Saitoh., Tsutomu Suzuki., Minoru Narita., Junzo Kamei., Leon F.Tseng., Hirokazu Mizoguchi., Hiroshi Nagase, TRK-820, a Selective \u03ba-Opioid Agonist, Produces Potent Antinociception in Cynomolgus Monkeys, The Japanese Journal of Pharmacology, 85 (2001) 282\u2013290.","DOI":"10.1254\/jjp.85.282"},{"key":"10.1016\/j.bioorg.2023.106869_b0610","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstrom","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bioorg.2023.106869_b0615","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","article-title":"Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bioorg.2023.106869_b0620","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJNRD.S145720","article-title":"Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch((R)) capsules 2.5 mug) in 3,762 hemodialysis patients with intractable pruritus","volume":"11","author":"Kozono","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.bioorg.2023.106869_b0625","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/jpet.104.073668","article-title":"Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo","volume":"312","author":"Wang","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2023.106869_b0630","doi-asserted-by":"crossref","first-page":"11054","DOI":"10.1021\/acs.jmedchem.9b00857","article-title":"Discovery of a Highly Selective and Potent kappa Opioid Receptor Agonist from N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message-Address Concept","volume":"62","author":"Xiao","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0635","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/acschemneuro.6b00321","article-title":"The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent kappa-Opioid Agonistic Activities","volume":"8","author":"Li","year":"2017","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2023.106869_b0640","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bmcl.2009.07.119","article-title":"Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton","volume":"20","author":"Li","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106869_b0645","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37041-7","article-title":"Molecular mechanism of biased signaling at the kappa opioid receptor","volume":"14","author":"El Daibani","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2023.106869_b0650","doi-asserted-by":"crossref","first-page":"12414","DOI":"10.1021\/acs.jmedchem.1c01082","article-title":"Discovery of an M-Substituted N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active kappa-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0655","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1021\/acs.jmedchem.5b00130","article-title":"C7beta-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin\/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors","volume":"58","author":"Cueva","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0660","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1111\/bph.14060","article-title":"Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed kappa\/mu receptor antagonist properties, in mice","volume":"175","author":"Almatroudi","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0665","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1016\/j.bmc.2018.07.020","article-title":"7beta-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues","volume":"26","author":"Sun","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0670","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1021\/acs.jmedchem.2c00014","article-title":"SLL-627 is a highly selective and potent kappa opioid receptor (kor) agonist with an unexpected nonreduction in locomotor activity","volume":"65","author":"Kong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106869_b0675","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0378-8741(88)90121-3","article-title":"Ethnopharmacology of kratom and the Mitragyna alkaloids","volume":"23","author":"Jansen","year":"1988","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2023.106869_b0680","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1248\/cpb.52.916","article-title":"Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa","volume":"52","author":"Takayama","year":"2004","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2023.106869_b0685","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cmdc.202100029","article-title":"Synthesis and assessment of fused beta-carboline derivatives as kappa opioid receptor agonists","volume":"16","author":"Yadav","year":"2021","journal-title":"ChemMedChem"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823005308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823005308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:52:19Z","timestamp":1758617539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823005308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":137,"alternative-id":["S0045206823005308"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106869","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Historical perspectives and recent advances in small molecule ligands of selective\/biased\/multi-targeted \u03bc\/\u03b4\/\u03ba opioid receptor (2019\u20132022)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106869"}}